Bronchiolitis Obliterans, Bronchiolitis Obliterans Syndrome, Obliterative Bronchiolitis
Conditions
Keywords
single and double transplant
Brief summary
The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.
Detailed description
This is a Phase III, multicenter, open-label, extension clinical trial of L-CsA for the treatment of BOS. Enrollment will be limited to patients who have completed 48 weeks participation in either the BT-L-CsA-301-SLT (BOSTON-1) or BT-L-CsA-302-DLT (BOSTON-2) trial. All patients in this clinical trial will receive L-CsA in addition to SoC, regardless of the randomization arm in prior trials. IMP will be administered by BID inhalation (morning/evening) using the L-CsA eFlow. Patients who did not receive L-CsA in BOSTON-1 or BOSTON-2 must remain in the clinic for at least 4 hours for observation after the first inhalation. At all subsequent visits, one dose administered via inhalation will be monitored by the clinical trial center personnel. In case patients receiving L-CsA undergo the last visit for BOSTON-1 or BOSTON-2 (Visit 9) on the same day as for Visit 1 for BOSTON-3, they will take the first dose for Boston 3 in the evening of this day. This first dose will not be supervised by the site staff. Nebulization time per inhalation dose is approximately 6-10 minutes for the 5 mg dose and 9-13 minutes for the 10 mg dose. Inhalations will be performed BID approximately 12 hours apart through a mouthpiece by slow and deep respiration using the L-CsA eFlow. A high efficiency particulate air filter is used to prevent environmental contamination during exhalation.
Interventions
DRUGLiposomal Cyclosporine A 5 mg
delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
DRUGLiposomal Cyclosporine A 10 mg
delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Sponsors
Zambon SpA
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients who have completed all visits through the End of Treatment Visit in either BOSTON-1 or BOSTON-2, did not withdraw informed consent, and did not prematurely terminate study drug administration. 2. Patients should be on a three-drug maintenance regimen of immunosuppressive agents including tacrolimus or another CNI, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone. 3. Patients capable of understanding the purposes and risks of the clinical trial, who have given written informed consent and agree to comply with the clinical trial requirements/visit schedules, and who are capable of aerosol inhalation. 4. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to Visit 1 and must agree to use one of the methods of contraception listed in Appendix II through their End of Study Visit.
Exclusion criteria
1. Known hypersensitivity to L-CsA or to cyclosporine A. 2. Patients who experienced an AE related to study drug that led to permanent study drug discontinuation in BOSTON-1 or BOSTON-2. 3. Patients with new onset of malignancy while participating in BOSTON-1 or BOSTON-2, including post-transplant lymphoproliferative disorder, with the exception of treated, localized basal and squamous cell carcinomas. 4. Pregnant women or women who are unwilling to use appropriate birth control to avoid pregnancy through their End of Study Visit. 5. Women who are currently breastfeeding. 6. Receipt of an investigational drug, other than L-CsA, as part of a clinical trial within 4 weeks prior to Visit 1. This is defined as any treatment that is implemented under an Investigational New Drug (IND) or compassionate use. 7. Patients who are currently participating in an interventional clinical trial, other than BOSTON-1 or BOSTON-2. 8. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary procedures. 9. Any co-existing medical condition that in the Investigator's judgment will substantially increase the risk associated with the patient's participation in the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in FEV1 from Baseline to Week 24 | Baseline to Week 24 | FEV1 is the Forced Expiratory Volume in One Second |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in FEV1 from Baseline to Week 48 | Baseline to Week 48 | FEV1 is the Forced Expiratory Volume in One Second |
| Mean change in FEV1 from Baseline to End of Study | Baseline to end of study, approximately 2 years | FEV1 is the Forced Expiratory Volume in One Second |
| Mean change in FEV1/FVC from Baseline to Week 24 | Baseline to Week 24 | FEV1/FVC is the ratio between Forced Expiratory Volume in One Second and Forced Vital Capacity. |
| Mean change in FEV1/FVC from Baseline to Week 48 | Baseline to Week 48 | FEV1/FVC is the ratio between Forced Expiratory Volume in One Second and Forced Vital Capacity. |
| Time to Progression of BOS | Baseline to End of Study, approximately 2 years | The Progression of BOS is defined as the earliest of: * Absolute decrease from baseline in FEV1 \>/= 10% or \>/= 200 mL and absolute decrease in FEV1/FVC of \> 5%, OR * Change in BOS severity (according to criteria in Verleden 2019), OR * Re-transplantation, OR * Death from respiratory failure |
Countries
Austria, Belgium, Denmark, France, Germany, Israel, Spain, United Kingdom, United States
Contacts
STUDY_DIRECTORPaola R Castellani, MD
Zambon SpA, Chief Medical Officer
Outcome results
None listed